ACTRN12616000064404招募中未知
ACURATE neo Trademark Aortic Bioprosthesis for Implantation using the ACURATE TF Trademark Transfemoral Delivery System in Patients with Severe Aortic Stenosis in an Australian Population
Reid Healthcare0 个研究点目标入组 100 人开始时间: 2016年1月21日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •The inclusion criteria are as below:
- •1. Study participant is 18 years or older
- •2. STS score is greater than or equal to 4; and/or heart team (at least one interventional cardiologist and one cardiac surgeon) agree on eligibility including assessment that TAVR is appropriate.
- •3. Study participant has severe aortic stenosis with mean gradient is greater than or equal to 40mmHg or jet velocity greater than or equal to 4.0 m/s and/or an initial aortic valve area (AVA) of less than or equal to 0.8 cm2 or indexed EOA is less than 0.5 cm2/m2.
- •4. Study participant is symptomatic from his/her aortic valve stenosis, as demonstrated by
- •New York Heart Association (NYHA) Functional Class II or greater.
- •5. Study participant is willing to participate in the study, provides signed Informed
- •Consent/Data Authorization Form and authorizes the sharing of data in the study
- •6. The study participant and treating physician agree the study participant will return for all
- •required post-procedure follow-up visits
排除标准
- •The exclusion criteria are as below:
- •1. Native aortic annulus size less than 21mm or greater than 27mm
- •2. Evidence of an acute myocardial infarction less than or equal to 1 month before the intended treatment
- •3. Echocardiographic evidence of intracardiac mass, thrombus or vegetation
- •4. Recent (within 3 months) cerebrovascular accident (CVA) or transient ischemic attack (TIA)
- •5. Severe dementia (as evidenced in medical history)
- •6. Estimated life expectancy is less than 12 months
- •7. Currently participating in an investigational drug or another device trial (excluding registries)
- •8. Active bacterial endocarditis within 6 months of the intended TAVR procedure
- •9. Pregnancy or intent to become pregnant prior to completion of all protocol follow-up
- •requirement
- •10. Study participant cannot comply with study requirements, including follow-up visits and tests
研究者
相似试验
撤回
不适用
ACURATE TA* Transapical Aortic Bioprosthesis for Implantation in Patients with Severe Aortic StenosisSevere Aortic Stenosis1008220610003216NL-OMON37451SYMETIS S.A.10
已完成
3 期
ACURATE TF Transfemoral Aortic Bioprosthesis for Implantation in patients with severe aortic stenosisI35.0Aortic (valve) stenosisDRKS00013491Symetis SA39
已完成
不适用
ACURATE Neo™ Aortic Bioprosthesis for Implantation Using the ACURATE TA™ LP Transapical Delivery System in Patients With Severe Aortic StenosisAortic StenosisNCT02986737Symetis SA15
已完成
不适用
ACURATE Neo™ TA Delivery System in Patient With Severe Aortic StenosisAortic StenosisNCT02950428Symetis SA60
已完成
不适用
ACURATE Neo™ AS Aortic Bioprosthesis for Implantation Using the ACURATE neoTM AS TF Transfemoral Delivery System in Patients With Severe Aortic StenosisAortic StenosisNCT02909556Symetis SA120